EP2056933A1 - Dispositif de production d'un champ électromagnétique pulsé au moyen d'une commande d'impulsions - Google Patents

Dispositif de production d'un champ électromagnétique pulsé au moyen d'une commande d'impulsions

Info

Publication number
EP2056933A1
EP2056933A1 EP07819963A EP07819963A EP2056933A1 EP 2056933 A1 EP2056933 A1 EP 2056933A1 EP 07819963 A EP07819963 A EP 07819963A EP 07819963 A EP07819963 A EP 07819963A EP 2056933 A1 EP2056933 A1 EP 2056933A1
Authority
EP
European Patent Office
Prior art keywords
pulse
pulses
microcirculation
blood
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07819963A
Other languages
German (de)
English (en)
Other versions
EP2056933B1 (fr
Inventor
Peter Gleim
Rainer Klopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2056933A1 publication Critical patent/EP2056933A1/fr
Application granted granted Critical
Publication of EP2056933B1 publication Critical patent/EP2056933B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Definitions

  • the invention relates to a device for generating a pulsed electromagnetic field with pulse control.
  • EP 0 594 655 B1 discloses a device consisting of generator and transmitter, with which an ion transport of intracorporeal electrolyte liquids into and through vessel walls is to take place and in which the applied pulsed
  • EP 0 995 463 B1 claims a device for influencing biological processes in a living tissue, in which pulses are delivered to the tissue in which the amplitude of each individual pulse corresponds to a mathematical relationship with the e-function e sinCx high Time course and b is the number of superimposed pulses.
  • the signal forms generated by the known devices should either improve muscle formation and joint regeneration or stimulate metabolic processes.
  • the invention has for its object to provide a device with which other characteristics of body functions can be improved by certain pulses of a pulsating magnetic field.
  • an apparatus for generating a pulsed electromagnetic field with pulse control comprising a pulse generator connected to a coil for generating an electromagnetic field, characterized in that the pulses emanating from the pulse generator represent periodic pulses, the rising and falling envelopes with harmonic or anharmonic waveforms within the envelopes, and that the pulse train is in the range of 1 pulse per 20 minutes to 4 pulses per minute, and that the control of pulse train, pulse width, pulse type, and electromagnetic flux density are based on measurement data obtained by noninvasive vital microscopic, spectrometric, laser Doppler or oxygen partial pressure measuring methods from a target tissue reproduce features of the microcirculation of the blood, whereby for the type of function such pulses with exponential functions a are taken.
  • microcirculation the flow of blood cells and blood plasma in the smallest blood vessels (with diameters ⁇ 200 microns), is the most functionally important part of the human bloodstream, as here the mass transfer is realized with the cells of an organ tissue. This concerns the transport of oxygen and substrate to the cells and the removal of metabolic end products.
  • the respective functional state of the microcirculation of an organ determines the rule width for an adaptation of the micro perfusion to changing metabolic needs and thus the organ function.
  • an undisturbed microcirculation is a prerequisite for an unhindered course of the first steps of an immunological reaction.
  • microcirculation has been at the center of clinical-pathophysiological research for some time.
  • vasomotion the investigation of possible influences on the local regulation of the microcirculation, in particular of the autorhythmic contraction movements of the smooth vessel wall musculature in arteriolar and venular microvessels
  • the vasomotor functional state essentially determines the adaptation width of the microcirculation to changing metabolic needs and thus the local control range of the microcirculation.
  • measurement data from the microcirculation of the blood are used for the control of pulses of an electromagnetic field.
  • These data are selected from the group consisting of venous oxygen depletion, number of blood cell perfused nodules, venular flow, local hematocrit in a microvessel, local hematocrit in all microvessels, spontaneous arteriolar vasomotion, venous vasomotion state , the number of adherent white blood cells on a defined venule inner wall, the local concentration changes of substances in the tissue. It is advantageous to use several of these features.
  • the absolute difference in oxygen saturation of hemoglobin in the afferent arterioles and efferent venules of the network of a selected tissue target is determined.
  • the target is tissue sections of the skin or intestine which have the targeted blood vessel networks of the organism and which are further among the immunologically active organs, and which are further readily accessible for non-invasive measurements.
  • nNP The number of blood cell-perfused nodes in the defined microvascular network, nNP, is the number of blood cell-perfused branching sites in this network used as a measure of the distribution state of the blood.
  • the venular flow flow Qven and the arteriolar flow Qart is the particle flow (blood cell flow) in defined venules or arterioles. It is given in ⁇ m 3 / s.
  • the local hematocrit in a blood vessel also called the hematocrit tube, Hk t , is the hematocrit in a particular microvessel. It is expressed as a percentage change compared to baseline.
  • the hematocrit of the microcirculation Hk MC is measured in all microvessels with diameters ⁇ 200 ⁇ m.
  • the arteriolar (or venous) vasomotion state, A VM is determined by determining the path-time diagram of the autorhythmic contraction movements of smooth muscle cells of the arteriolar vascular wall (measurement of the distance normal to the microvessel longitudinal axis from endothelial surface to opposite endothelial surface to equidistant Measuring points per second, 60 measured values, determination of the composite vibration, FOURIER analysis, determination of the amplitude-frequency spectrum).
  • the criterion is the area A under the envelope of the amplitude-frequency spectrum of the arteriolar vasomotion (a composite vibration). The value is given as a percentage change compared to the initial values,
  • vasomotion Prophylactically and therapeutically relevant is an influencing of the disturbed vasomotion towards a physiological vasomotion rhythm, i. the "imprinting" of a physiological vasomotion rhythm in case of illness.
  • the vasomotion movements of arteriolar and venular microvessels are significantly altered (usually significantly slowed down, sometimes only less than 1 to 2 vasomotion movements over several minutes).
  • the disturbed vasomotion i. the "imprinting" of a physiological vasomotion rhythm in case of illness.
  • the vasomotion movements of arteriolar and venular microvessels are significantly altered (usually significantly slowed down, sometimes only less than 1 to 2 vasomotion movements over several minutes).
  • Vasomotion To guide in the field of physiological vasomotion (about 1-10, especially 1-4 vasomotion movements per minute). The same applies to pathological conditions with considerably accelerated vasomotion.
  • the device of the invention makes use of the above-mentioned specific values measured especially before the treatment the microcirculation is based on extremely low frequency treatment.
  • the device according to the invention preferably generates pulse trains which are in the range from 1 pulse / 10 minutes to 2 pulses / 1 minute, preferably from 1 pulse / 5 minutes to 3 pulses / 1 minute, in particular from 1 pulse / 2 minutes to 1 Momentum / l minute. Illustrated in FIGS. 4a and 4b by way of example are such advantageous pulse sequences without reference to the intensity.
  • pulse train is understood to mean the distance of such oscillation averages (pulse maxiina) from each other which lie above the intensity zero line in an intensity-time diagram such as, for example, illustrated in FIG. 4c. If there is a base vibration which may be constant, stochastically different or sinusoidally different in intensity, as shown in Figs. 4d, 4e and 4f respectively, "pulse train” means the distance of such vibration maxima from each other well above the base vibration lies. Pulse train is thus the frequency of occurrence of maximum amounts of the envelope in the time unit.
  • This then likewise corresponds to the pulse sequence in the sense of the invention.
  • Such a pulse arrangement may be advantageous, i. to the o.g. Impulse or o.g. Pulse train (Fig. 4a and 4b) to add a hfreherfreguenten pulse with lower electromagnetic flux density B.
  • These additional pulses may vary in their amplitudes (and frequencies) in various ways, as illustrated by way of example in FIGS. 4c to 4h. They are generally 50 to 80 ⁇ T.
  • the width of a single pulse at 50 to 300 ms and the width of a base pulse at 10 to 60 ms; 80 to 200 ms or 20 to 40 ms are preferred.
  • the so-called "intensity” or momentum strength is physically the electromagnetic flux density B with the unit Tesla.
  • the pulses generated by the device according to the invention are emitted periodically and, in the case of graphic representation, are arc-shaped in their envelopes, such as sinusoidal or cosinusoidal to parabolic-like constructs.
  • envelopes Within the envelopes, harmonic oscillations of the same or different amplitude occur, which are also acceptable. can overlap with monic oscillations.
  • envelope is understood to mean the curve that touches the maxira of different amplitudes of a certain sequence of amplitudes and thus “envelops" this sequence in the rising and falling part (see FIG. 2). In superimposed anharmonic
  • the pulses correspond to a type of function whose rise and fall of the envelopes is approximately arcuate as in rectified currents.
  • the pulses are composite oscillations or waves, which are formed from a plurality of partial oscillations such as harmonic or anharmonic different amplitude and frequency, wherein the sub-frequencies are from - 20 to 3000 Hz.
  • the “envelope” approximately mirrors the course of the composite vibration or wave.
  • a function type of the pulse for the envelope which corresponds to the type of a rectified cosine current.
  • a rectified cosine stream in the development of a FOURIER series representation of periodic functions is as follows
  • Optimal treatment results are achieved by varying the signal (pulse) based on simultaneously measured microcirculation functionalities.
  • amplitudes and frequencies of the individual pulses, pulse sequences or pulse pauses or intensities can be changed.
  • Intensities from the nano-Tesla range to the milli-Tesla range are possible, e.g. 50 nT to 800 mT, but are usually in the micro-Tesla range at about 5-300 ⁇ T.
  • the device according to the invention can be used in healthy persons in terms of an increase in performance or in persons exposed to infection and / or stress, in older people with limited physical performance and reduced immune defense and also in case of illness.
  • the treatment of mammals is also within the scope of the invention.
  • the effects on vasomotion (feature A VM ) and the distribution state of the blood in the microvascular networks (feature nNP) are important for a prophylactic application and thus for the increase in physical performance and improved organ functions as a result of an expansion of the microcirculatory rule width.
  • the device according to the invention makes significantly larger and substantially longer lasting characteristic changes of the functional state of the microcirculation achieved.
  • the signal according to the invention shows a maximum of approximately 22%, remaining only light for a certain period of time declining at this altitude and only slowly decays at about 50 to 60 minutes. Overall, this results in a significantly improved overall effect.
  • Fig. I a Arctic impulse with steep rise and steep drop
  • Fig. 2 Envelope (dashed line) of an amplitude-modified wave
  • Fig. 4a preferred pulse train 2 per 1 minute
  • Fig. 4b pulse train 1 per 3 minutes
  • Fig. 4c Intensity-time diagram with pulse sequence 3 per minute (150 ms and 163 ⁇ T) with shorter pulse sequence pulses and lower intensity pulses (30 ms and 78 ⁇ T);
  • Fig. 4f section of a pulse train 1 pulse per
  • a pulse generator with which pulses are generated, which are supplied to an electromagnetic coil.
  • the coil is in contact with a skin surface (target tissue).
  • impulses are given to the target tissue at intervals of 1 day, 3 days, 6 days, 9 days and 12 days.
  • the measurement of the o.g. Parameter was carried out in each case 10 minutes after completion of Impulsgäbe.
  • Pulse type approximately rectified sinusoidal Pulse intensity: single pulse with 180 ⁇ T and a pulse width of 150 ms; additional basic pulse with 60 ⁇ T and a pulse width of 30 ms
  • Treatment sequence every other day
  • nNP The percentage change for nNP was already about 10% on the 3rd day and increased to about 24% on the 12th day.
  • Pulse train 30 per second
  • Pulse type special exponential function e sin ( ⁇ high 3!
  • Pulse intensity 50 ⁇ T with 30 ms pulse width
  • the percent change for A VM was about 3% on the 3rd day and increased to about 4% by the 12th day.
  • nNP The percent change for nNP was about 4% on the 3rd day and increased to about 6% by the 12th day. These changes do not represent therapeutically relevant changes and show that both pulse type and pulse sequence do not significantly affect the local microcirculation control mechanism.
  • the percentage change for A VM was already more than 9% on the 3rd day and increased to about 25% on the 12th day.
  • the percentage change for nNP was already about 12% on the 3rd day and increased to about 30% on the 12th day.
  • the percentage change for A VM was about 5% on the 3rd day and increased to about 8% on the 12th day.
  • the percent change for nNP was also about 5% on the 3rd day and increased to about 7% by the 12th day.
  • Example 3 A number of healthy, older subjects were treated in the same way as in Example 1. Number of subjects: 16
  • the percentage change for nNP was about as early as the 3rd day
  • the percentage change for A VM was about 4% on the 3rd day and increased to about 5% on the 12th day.
  • the percent change for nNP was about 5% on the 3rd day and increased to about 6% by the 12th day.
  • the percentage change for nNP was already about 8% on the 3rd day and increased to about 16% on the 12th day.
  • the percentage change for A VM was about 4% on the 3rd day and increased to about 5% on the 12th day.
  • the percent change for nNP was about 5% on the 3rd day and increased to about 6% by the 12th day.

Abstract

L'invention concerne un dispositif de production d'un champ électromagnétique pulsé, au moyen d'une commande d'impulsions, dispositif caractérisé en ce que les impulsions provenant du générateur d'impulsions représentent des impulsions périodiques qui présentent des courbes enveloppes montantes et descendantes, avec des variations d'oscillations harmoniques ou anharmoniques à l'intérieur des courbes enveloppes, en ce que la série d'impulsions se situe dans un domaine de 1 impulsion/20 minutes à 10 impulsions/1 minute, en ce que la série d'impulsions, le type de fonction de l'impulsion et la densité du flux électromagnétique sont commandés à partir de valeurs qui reproduisent, au moyen d'un procédé de mesure non invasive, à partir d'un tissu cible, des caractéristiques de microcirculation du sang, et en ce que, pour le type de fonction, des impulsions à fonctions exponentielles sont exclues. L'invention permet d'obtenir des améliorations bien plus prononcées et prolongées de la microcirculation.
EP07819963A 2006-08-28 2007-08-24 Dispositif de production d'un champ electromagnetique pulse au moyen d'une commande d'impulsions Active EP2056933B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006041365A DE102006041365B4 (de) 2006-08-28 2006-08-28 Vorrichtung zur Erzeugung eines pulsierenden elektromagnetischen Feldes mit Impulssteuerung
PCT/EP2007/058803 WO2008025731A1 (fr) 2006-08-28 2007-08-24 Dispositif de production d'un champ électromagnétique pulsé au moyen d'une commande d'impulsions

Publications (2)

Publication Number Publication Date
EP2056933A1 true EP2056933A1 (fr) 2009-05-13
EP2056933B1 EP2056933B1 (fr) 2010-10-27

Family

ID=38675623

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07819963A Active EP2056933B1 (fr) 2006-08-28 2007-08-24 Dispositif de production d'un champ electromagnetique pulse au moyen d'une commande d'impulsions

Country Status (9)

Country Link
US (1) US8216121B2 (fr)
EP (1) EP2056933B1 (fr)
KR (1) KR101049288B1 (fr)
CN (1) CN101553277B (fr)
AT (1) ATE485866T1 (fr)
CA (1) CA2662194C (fr)
DE (2) DE102006041365B4 (fr)
ES (1) ES2354033T3 (fr)
WO (1) WO2008025731A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020250A1 (fr) * 2007-07-26 2009-02-04 Johannes Josephus Maria Cuppen Dispositif et procédé de stimulation électromagnétique d'un processus au sein d'organismes vivants
US8667732B2 (en) 2009-01-29 2014-03-11 Peter Gleim Method for the treatment of plants using electromagnetic fields
WO2010086301A1 (fr) 2009-01-29 2010-08-05 Peter Gleim Système pour moduler une perfusion dans la microcirculation sanguine
CN101683534B (zh) * 2009-03-17 2013-08-14 北京农学院 一种非治疗用提高微血管自律运动振幅中药成分筛选方法
US8496571B2 (en) 2009-08-25 2013-07-30 Peter Gleim Apparatus for stimulating homeostatic autoregulatory mechanisms in the organism
ES2532961T3 (es) 2009-08-25 2015-04-06 Bemer International Ag Dispositivo para la estimulación de mecanismos autorreguladores locales y de orden superior de la homeostasis del organismo
DE102009043728A1 (de) * 2009-10-01 2011-04-07 Albert Hesse Verfahren zur Behandlung von Übergewicht
EP2468269A1 (fr) 2010-11-26 2012-06-27 Universitätsklinikum Münster Donneurs d'oxyde nitrique pour la thérapie des perturbations induites par une déficience d'oxyde nitrique de la microcirculation cérébrale
US9724535B1 (en) 2013-02-19 2017-08-08 Blugreen Technologies, Inc. Low frequency magnetic pulse variable resonator for actively influencing the interaction and intercommunication at the cellular level for biological organisms and molecular level of matter
AU2016258676A1 (en) * 2015-05-05 2017-11-30 Eth Zurich System and method for applying pulsed electromagnetic fields
DE102015009783A1 (de) 2015-07-27 2017-02-02 Kurt Becker Modulare Vorrichtung zur Erzeugung und Messung mehrdimensionaler, räumlich und zeitlich definierter schwacher Elektro-Magnetischer-Felder (sEMF)
US10918643B2 (en) 2015-09-16 2021-02-16 Westfaelische Wilhelms-Universitaet Muenster No-donors for the treatment of cerebrovascular vasospasms after brain hemorrhage
DE102016122691A1 (de) * 2016-11-24 2018-05-24 Bemer Int. AG Vorrichtung zur Beeinflussung biologischer Abläufe in einem lebenden Gewebe
EP3501599A1 (fr) 2017-12-19 2019-06-26 BEMER Int. AG Dispositif permettant de stimuler le réglage local de la microcirculation, procédé prophylactique ou thérapeutique ainsi qu'utilisation destiné à améliorer les caractéristiques représentatives de l'état de fonctionnement de la microcirculation
US10821294B2 (en) * 2018-03-02 2020-11-03 Yevgeniy Postrekhin Magnetic field optimization method and device for blood flow microcirculation enhancement
MY192775A (en) * 2018-04-12 2022-09-08 Teik Hock Lau Method and apparatus for the improvement ofmicrocirculation
US11020603B2 (en) 2019-05-06 2021-06-01 Kamran Ansari Systems and methods of modulating electrical impulses in an animal brain using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing
US11517760B2 (en) 2019-05-06 2022-12-06 Kamran Ansari Systems and methods of treating medical conditions using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03277381A (ja) 1990-03-27 1991-12-09 Matsushita Electric Works Ltd 低周波治療器
WO2003015626A2 (fr) 2001-08-14 2003-02-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Procede et dispositif permettant de determiner une valeur caracteristique relative a la circulation sanguine de regions tissulaires modifiees dans des organes d'etres vivants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340974C2 (de) * 1983-11-11 1994-07-07 Werner Dipl Phys Kraus Elektrotherapiegerät
DE4221739A1 (de) * 1991-07-09 1993-01-14 Fischer Ag Vorrichtung zum transport von ionen, insbesondere protonen
AU663948B2 (en) * 1992-06-12 1995-10-26 Kabushiki Kaisha Advance Electrical stimulator
DE4325071C2 (de) * 1993-07-19 1995-08-10 Lancaster Group Ag Präparat zur Durchblutungsförderung
GB2295093A (en) * 1995-03-30 1996-05-22 Vladimir Tsebenko Synchronised electro-magnetic therapy device
DE29718337U1 (de) * 1997-10-17 1999-02-18 Muntermann Axel Vorrichtung zur Magnetfeldtherapie
DE59801224D1 (de) * 1998-10-21 2001-09-20 Kafka Wolf A Vorrichtung und elektrisches oder elektromagnetisches Signal zur Beeinflussung biologischer Abläufe
US6440059B1 (en) 1999-10-14 2002-08-27 Cimex Biotech Lc Magnetohydrodynamic cardiac assist device
DE10304085A1 (de) * 2003-01-31 2004-08-12 Günther, Andreas Anordnung und Verfahren zur Durchführung einer Magnetfeldtherapie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03277381A (ja) 1990-03-27 1991-12-09 Matsushita Electric Works Ltd 低周波治療器
WO2003015626A2 (fr) 2001-08-14 2003-02-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Procede et dispositif permettant de determiner une valeur caracteristique relative a la circulation sanguine de regions tissulaires modifiees dans des organes d'etres vivants

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Eulersche Identität", WIKIPEDIA, 19 March 2010 (2010-03-19), pages 1 - 2, XP003026777
ANOYMOUS: "Hamatokrit", WIKIPEDIA, pages 1 - 2, XP003024848, Retrieved from the Internet <URL:http://de.wikipedia.org/wiki/H%C3%A4matokrit>
ANOYMOUS: "Trigonometrisches Polynom", WIKIPEDIA, 25 April 2010 (2010-04-25), pages 1, XP003026776
KLOPP R.: "Methoden zur Untersuchung der Mikrozirkulation", MIKROZIRKULATION, vol. 1, 2008, pages 133 - 134, XP003026781
R.C. KLOPP: "Bio-Elektro-Magnetische-Energie Regulations-therapie: Wertvoller Komplementär-therapeutischer Einsatz der BEMER-Therapie", BEMER-THERAPIE, January 2006 (2006-01-01), pages 8 - 20, XP003026779
ROSENSPIRE A.J. ET AL: "Real-time control of neutrophil metabolism by very weak ultra-low frequency pulsed magnetic fields", BIOPHYSICAL JOURNAL, vol. 88, May 2005 (2005-05-01), pages 3334 - 3347, XP003024849
SCHULZ J. ET AL: "Magnetfeldtherapie: Komplementär-therapeutisch sinnvoll oder Unsinn?", 2005, pages 1 - 11, XP003026780
TRAIKOV. E. ET AL: "Changes of the magnitude of Arteriolar vasomotion during and after ELF_EMF exposure in vivo", BIOELECTROMAGNETICS CURRENT CONCEPTS, vol. 5, 2006, pages 377 - 389, XP003024847
W. BOHN: "Neue Studien bringen weitere aufklärung medizinisch-physiologischer zusammenhänge bei anwendung der BEMER-Therapie", BEMER-THERAPIE, January 2006 (2006-01-01), pages 4 - 7, XP003026778

Also Published As

Publication number Publication date
WO2008025731A1 (fr) 2008-03-06
DE102006041365B4 (de) 2010-09-02
CN101553277B (zh) 2011-05-18
DE102006041365A1 (de) 2008-03-13
KR20090042262A (ko) 2009-04-29
US8216121B2 (en) 2012-07-10
CA2662194A1 (fr) 2008-03-06
CN101553277A (zh) 2009-10-07
EP2056933B1 (fr) 2010-10-27
ES2354033T3 (es) 2011-03-09
DE502007005486D1 (de) 2010-12-09
CA2662194C (fr) 2015-10-27
US20100057146A1 (en) 2010-03-04
ATE485866T1 (de) 2010-11-15
KR101049288B1 (ko) 2011-07-14

Similar Documents

Publication Publication Date Title
EP2056933B1 (fr) Dispositif de production d&#39;un champ electromagnetique pulse au moyen d&#39;une commande d&#39;impulsions
EP3513836B1 (fr) Applicateur de champ magnétique à une allure de signal des courants de bobine utilisés en forme de rampe
Clifton et al. Receptive fields of unmyelinated ventral root afferent fibres in the cat.
EP2470265B1 (fr) Dispositif de stimulation de mécanismes autorégulateurs locaux et supérieurs de l&#39;homéostasie de l&#39;organisme
Costa et al. From threat to safety: Instructed reversal of defensive reactions
WO1997023160A2 (fr) Procede de retroaction biologique et dispositif permettant d&#39;influer sur le psychisme humain
EP2470266B1 (fr) Dispositif de stimulation de mécanismes autorégulateurs de l&#39;homéostasie de l&#39;organisme
WO2018095589A1 (fr) Dispositif pour agir sur des processus biologiques dans un tissu vivant
EP3544676A1 (fr) Dispositif pour agir sur des processus biologiques dans un tissu vivant
EP2166933A1 (fr) Procédé pour déterminer une modification quasi continue de la pression sanguine dans un flux sanguin pulsatile
DE69726883T2 (de) Magnetotherapeutische vorrichtung
DE102004024655B4 (de) Vorrichtung zur Probanden-Stimulation mittels zeitveränderlicher Mikroströme
WO2019121622A1 (fr) Dispositif et procédé pour stimuler la régulation locale de la microcirculation
Dehghanpour et al. Improvement of working memory performance by parietal upper alpha neurofeedback training
DE102004026901A1 (de) Verfahren und Vorrichtung zur Messung informationsabhängiger physiologischer Daten des menschlichen oder tierischen Körpers
DE102021101671A1 (de) Vorrichtung zur Magnetfeldtherapie
Li et al. Morphological and electrophysiological evidence for regeneration of transected spinal cord fibers and restoration of motor functions in adult rats
DE102021108818A1 (de) Vorrichtung und Verfahren zur Verbesserung der Mikrozirkulation
RU2096048C1 (ru) Способ стимуляции костно-мозгового кроветворения
DE102006033304A1 (de) Vorrichtung zur Erzeugung eines elektromagnetischen Feldes zur Anwendung auf menschliches und tierisches Gewebe zur Produktionssteuerung von Phosphidiesterasen (PDE)-Typ-5-Hemmer
Best Reflections on Joseph Lister's Edinburgh experiments on vaso-motor control
Ott Long-term plasticity of speech-related auditory functions in professional musicians
Skopalik et al. TEST OF COMPLEX NANOSTRUCTURES AS GENE DELIVERY SYSTEM TO CARDIAC CELLS
DE102007000799A1 (de) Verfahren zur Reduktion von Altershauterscheinungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KLOPP, RAINER

Inventor name: GLEIM, PETER

17Q First examination report despatched

Effective date: 20090730

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

REF Corresponds to:

Ref document number: 502007005486

Country of ref document: DE

Date of ref document: 20101209

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20110225

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110227

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110228

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110127

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E010263

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110728

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502007005486

Country of ref document: DE

Effective date: 20110728

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20101027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101027

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: BEMER INTERNATIONAL AG, LI

Free format text: FORMER OWNER: GLEIM, PETER, LI

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 502007005486

Country of ref document: DE

Representative=s name: GULDE & PARTNER PATENT- UND RECHTSANWALTSKANZL, DE

Effective date: 20140417

Ref country code: DE

Ref legal event code: R081

Ref document number: 502007005486

Country of ref document: DE

Owner name: BEMER INTERNATIONAL AG, LI

Free format text: FORMER OWNER: GLEIM, PETER, TRIESEN, LI

Effective date: 20140417

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20140527

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: BEMER INTERNATIONAL AG

Effective date: 20140605

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20140522 AND 20140528

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: BEMER INTERNATIONAL AG, LI

Free format text: FORMER OWNER(S): GLEIM, PETER, LI

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: ETIKE'IP S.A.S. DI ALESSANDRO MARCIANO & C., IT

Effective date: 20140805

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 485866

Country of ref document: AT

Kind code of ref document: T

Owner name: BEMER INTERNATIONAL AG, LI

Effective date: 20160601

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230823

Year of fee payment: 17

Ref country code: LU

Payment date: 20230821

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230831

Year of fee payment: 17

Ref country code: GB

Payment date: 20230824

Year of fee payment: 17

Ref country code: FI

Payment date: 20230823

Year of fee payment: 17

Ref country code: ES

Payment date: 20230918

Year of fee payment: 17

Ref country code: CZ

Payment date: 20230814

Year of fee payment: 17

Ref country code: CH

Payment date: 20230902

Year of fee payment: 17

Ref country code: AT

Payment date: 20230818

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230823

Year of fee payment: 17

Ref country code: HU

Payment date: 20230817

Year of fee payment: 17

Ref country code: FR

Payment date: 20230821

Year of fee payment: 17

Ref country code: DE

Payment date: 20230829

Year of fee payment: 17

Ref country code: BE

Payment date: 20230822

Year of fee payment: 17